[1] 王玮, 王琳. 黄酮类化合物的研究进展[J]. 沈阳医学院学报, 2002, 4(2): 115-119.
[2] Cai Y, Sun M, Xing J, et al. Structureradical scavenging activity relationships of phenolic compounds from traditional Chinese medicinal plants[J]. Life Sciences, 2006, 78: 2872-2888.
[3] VasquezMartinez Y, Ohri R V, Kenyon V, et al. Structureactivity relationship studies of flavonoids as potent inhibitors of human platelet 12hLO, reticulocyte 15hLO1, and prostate epithelial 15hLO2[J]. Bioorganic and Medicinal Chemistry, 2007, 15: 7408-7425.
[4] Brunskole M, Zorko K, Kerbler V, et al. Trihydroxynaphthalene reductase of Curvularia lunataA target for flavonoid action[J]. ChemicoBiological Interactions, 2009, 178(1): 259-267.
[5] Liu A L, Wang H, Lee S, et al. Structureactivity relationship of flavonoids as influenza virus neuraminidase inhibitors and their in vitro antiviral activities[J]. Bioorganic & Medicinal Chemistry, 2008, 16(15): 7141-7147.
[6] Plochmann K, Korte G, Koutsilieri E, et al. Structureactivity relationships of flavonoidinduced cytotoxicity on human leukemia cells[J]. Archives of Biochemistry and Biophysics, 2007, 460(1): 1-9.
[7] Cárdenas M, Marder M, Blank V C, et al. Antitumor activity of some natural flavonoids and synthetic derivatives on various human and murine cancer cell lines[J]. Bioorganic & Medicinal Chemistry, 2006, 14(9): 2966-2971.
[8] 王希龙, 邱文秀, 贾中明, 等. 乳腺癌的诊断现状及最新进展[J]. 中国综合临床, 2012, 28(8): 787-788.
[9] 徐光炜, 胡永昇, 阚秀. 中国10万妇女乳腺癌筛查初探[J]. 中国肿瘤, 2010, 19(9): 565-568.
[10] 开贞, 玉奎. 临床常用药物[M]. 济南: 山东科学技术出版社, 2005: 38.
[11] Ramachandran C, Melnick S J. Multidrug resistance in human tumorsmolecular diagnosis and clinical significance〖JP〗[J]. Molecular Diagnosis, 1999, 4(2): 81-94.
[1]彭钰芳,许传莲.黄酮类化合物抑制肿瘤细胞增殖活性及构效关系[J].浙江理工大学学报,2011,28(02):267.
[2]吴登伟,王毅刚,郑婷婷,等.黄酮类化合物与阿霉素联用对乳腺癌细胞MCF7凋亡的影响[J].浙江理工大学学报,2015,33-34(自科5):706.
WU Deng wei,WANG Yi gang,ZHENG Ting ting,et al.Inhibitory Effect of Doxorubicine Combined with Flavonoids on MCF7 Breast Cancer Cell[J].Journal of Zhejiang Sci-Tech University,2015,33-34(自科4):706.